Announced that six COVID-19 patients treated with mavrilimumab in Italy all responded to treatment, and 3 patients were discharged within 5 days. A follow-on controlled study in Italy is planned. Shares closed the week up 43% to $17.91. - BioPharmCatalyst
Breaking through the recent top will be a strong indicator for further upside movement. Hovering aorund the recent top without a follow through could indicate not enough buying power and distribution is taking place and a strong move in the downside direction could occur.
Take the potential support levels with a grain of salt as there is only 52.23M Shares Outstanding and a share float of 18.79M. Short Float is currently 7.19%
Consensus Analyst Profit Target = 25.50$ according to MarketBeat Most recent: 4/1/2020 Bank of America 25$